Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Li, Chenggong
679  Ergebnisse:
Personensuche X
?
1

Targeting autophagy overcomes cancer‐intrinsic resistance t..:

Tang, Lu ; Zhang, Huan ; Zhou, Fen...
Cancer Communications.  44 (2024)  3 - p. 408-432 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Off-the-shelf CAR-T cell therapies for relapsed or refracto..:

Kang, Yun ; Li, Chenggong ; Mei, Heng
Journal of Hematology & Oncology.  17 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
3

Treatment of multiple myeloma: What is the impact on T-cell..:

Li, Chenggong ; Wang, Xindi ; Xu, Jia..
Therapeutic Advances in Hematology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.1177/..
 
?
4

Targeting CD22 for B-cell hematologic malignancies:

Xu, Jia ; Luo, Wenjing ; Li, Chenggong.
Experimental Hematology & Oncology.  12 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
5

Bruton tyrosine kinase inhibitors preserve anti-CD19 chimer..:

Luo, Wenjing ; Li, Chenggong ; Wu, Jianghua...
Cytotherapy.  25 (2023)  7 - p. 739-749 , 2023
Link: https://doi.org/10.1016/..
 
?
6

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH RE..:

Luo, Wenjing ; LI, Chenggong ; Zhang, Yinqiang...
HemaSphere.  7 (2023)  S3 - p. e4325339 , 2023
Link: https://doi.org/10.1097/..
 
?
7

Bispecific CS1-BCMA CAR-T cells are clinically active in re..:

Li, Chenggong ; Xu, Jia ; Luo, Wenjing...
Leukemia.  38 (2023)  1 - p. 149-159 , 2023
Link: https://doi.org/10.1038/..
 
?
8

IL-10 plus the EASIX score predict bleeding events after an..:

Wang, Xindi ; Li, Chenggong ; Luo, Wenjing...
Annals of Hematology.  102 (2023)  12 - p. 3575-3585 , 2023
Link: https://doi.org/10.1007/..
 
?
9

Novel CD19-specific γ/δ TCR-T cells in relapsed or refracto..:

Li, Chenggong ; Zhou, Fen ; Wang, Jing...
Journal of Hematology & Oncology.  16 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
10

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS A..:

Wang, Xindi ; LI, Chenggong ; Luo, Wenjing...
HemaSphere.  7 (2023)  S3 - p. e46287f9 , 2023
Link: https://doi.org/10.1097/..
 
?
11

Allogenic and autologous anti-CD7 CAR-T cell therapies in r..:

Zhang, Yinqiang ; Li, Chenggong ; Du, Mengyi...
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
12

Plasma proteomic and metabolomic signatures of B‐ALL patien..:

Wu, Jianghua ; Tang, Lu ; Du, Mengyi...
Clinical and Translational Medicine.  13 (2023)  3 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
13

Therapeutic targets and signaling pathways of active compon..:

Cao, Hongwen ; Wang, Dan ; Gao, Renjie...
PeerJ.  10 (2022)  - p. e13481 , 2022
Link: https://doi.org/10.7717/..
 
?
14

Multiple immunoglobulin isotype switch after bispecific CAR..:

Li, Chenggong ; Liu, Jiachen ; Deng, Jun...
British Journal of Haematology.  200 (2022)  4 - p. 528-531 , 2022
Link: https://doi.org/10.1111/..
 
?
15

Timing of Tocilizumab Administration Under the Guidance of ..:

Zhang, Yinqiang ; Zhou, Fen ; Wu, Zhuolin...
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
1-15